Novo Nordisk's Wegovy Gains US Approval for MASH Treatment
TL;DR Summary
Novo Nordisk's Wegovy has received accelerated FDA approval to treat MASH, making it the first GLP-1 therapy approved for this liver condition, based on promising early trial results, with plans for approval in Europe and Japan.
- Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH Reuters
- Novo Nordisk’s Wegovy Gets US Approval for Liver Disease Bloomberg.com
- Novo Nordisk’s obesity drug Wegovy cleared to treat MASH statnews.com
- Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis PR Newswire
- Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
92%
454 → 36 words
Want the full story? Read the original article
Read on Reuters